Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

The efficacy versus toxicity profile of combination virotherapy and TLR immunotherapy highlights the danger of administering TLR agonists to oncolytic virus-treated mice.

Rommelfanger DM, Compte M, Diaz RM, Ilett E, Alvarez-Vallina L, Thompson JM, Kottke TJ, Melcher A, Vile RG.

Mol Ther. 2013 Feb;21(2):348-57. doi: 10.1038/mt.2012.204. Epub 2012 Sep 25. Erratum in: Mol Ther. 2013 Apr;21(4):913. Grau, Marta C [corrected to Compte, Marta].

2.

VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):150-8. doi: 10.1038/mt.2010.225. Epub 2010 Oct 19.

3.

Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.

Galivo F, Diaz RM, Wongthida P, Thompson J, Kottke T, Barber G, Melcher A, Vile R.

Gene Ther. 2010 Feb;17(2):158-70. doi: 10.1038/gt.2009.161. Epub 2009 Dec 17.

4.

Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.

Galivo F, Diaz RM, Thanarajasingam U, Jevremovic D, Wongthida P, Thompson J, Kottke T, Barber GN, Melcher A, Vile RG.

Hum Gene Ther. 2010 Apr;21(4):439-50. doi: 10.1089/hum.2009.143.

5.

Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors.

Qiao J, Wang H, Kottke T, Diaz RM, Willmon C, Hudacek A, Thompson J, Parato K, Bell J, Naik J, Chester J, Selby P, Harrington K, Melcher A, Vile RG.

Gene Ther. 2008 Apr;15(8):604-16. doi: 10.1038/sj.gt.3303098. Epub 2008 Feb 28.

6.

Definitive Management of Oligometastatic Melanoma in a Murine Model Using Combined Ablative Radiation Therapy and Viral Immunotherapy.

Blanchard M, Shim KG, Grams MP, Rajani K, Diaz RM, Furutani KM, Thompson J, Olivier KR, Park SS, Markovic SN, Pandha H, Melcher A, Harrington K, Zaidi S, Vile R.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):577-87. doi: 10.1016/j.ijrobp.2015.07.2274. Epub 2015 Jul 26.

7.

Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy.

Ilett E, Kottke T, Thompson J, Rajani K, Zaidi S, Evgin L, Coffey M, Ralph C, Diaz R, Pandha H, Harrington K, Selby P, Bram R, Melcher A, Vile R.

Gene Ther. 2017 Jan;24(1):21-30. doi: 10.1038/gt.2016.70. Epub 2016 Oct 25.

8.

Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.

Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R.

Mol Ther. 2011 Jan;19(1):140-9. doi: 10.1038/mt.2010.224. Epub 2010 Oct 26.

9.

Activating systemic T-cell immunity against self tumor antigens to support oncolytic virotherapy with vesicular stomatitis virus.

Wongthida P, Diaz RM, Pulido C, Rommelfanger D, Galivo F, Kaluza K, Kottke T, Thompson J, Melcher A, Vile R.

Hum Gene Ther. 2011 Nov;22(11):1343-53. doi: 10.1089/hum.2010.216. Epub 2011 Apr 11.

10.

Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.

Lemay CG, Rintoul JL, Kus A, Paterson JM, Garcia V, Falls TJ, Ferreira L, Bridle BW, Conrad DP, Tang VA, Diallo JS, Arulanandam R, Le Boeuf F, Garson K, Vanderhyden BC, Stojdl DF, Lichty BD, Atkins HL, Parato KA, Bell JC, Auer RC.

Mol Ther. 2012 Sep;20(9):1791-9. doi: 10.1038/mt.2012.128. Epub 2012 Jul 3.

11.

Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.

Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG.

Cancer Res. 2009 Oct 1;69(19):7713-20. doi: 10.1158/0008-5472.CAN-09-1013. Epub 2009 Sep 22.

12.

Type III IFN interleukin-28 mediates the antitumor efficacy of oncolytic virus VSV in immune-competent mouse models of cancer.

Wongthida P, Diaz RM, Galivo F, Kottke T, Thompson J, Pulido J, Pavelko K, Pease L, Melcher A, Vile R.

Cancer Res. 2010 Jun 1;70(11):4539-49. doi: 10.1158/0008-5472.CAN-09-4658. Epub 2010 May 18.

13.

Retargeting Oncolytic Vesicular Stomatitis Virus to Human T-Cell Lymphotropic Virus Type 1-Associated Adult T-Cell Leukemia.

Betancourt D, Ramos JC, Barber GN.

J Virol. 2015 Dec;89(23):11786-800. doi: 10.1128/JVI.01356-15. Epub 2015 Sep 16.

14.

Use of biological therapy to enhance both virotherapy and adoptive T-cell therapy for cancer.

Kottke T, Diaz RM, Kaluza K, Pulido J, Galivo F, Wongthida P, Thompson J, Willmon C, Barber GN, Chester J, Selby P, Strome S, Harrington K, Melcher A, Vile RG.

Mol Ther. 2008 Dec;16(12):1910-8. doi: 10.1038/mt.2008.212. Epub 2008 Sep 30.

15.

Safety studies on intravenous administration of oncolytic recombinant vesicular stomatitis virus in purpose-bred beagle dogs.

LeBlanc AK, Naik S, Galyon GD, Jenks N, Steele M, Peng KW, Federspiel MJ, Donnell R, Russell SJ.

Hum Gene Ther Clin Dev. 2013 Dec;24(4):174-81. doi: 10.1089/humc.2013.165.

16.

The strength of the T cell response against a surrogate tumor antigen induced by oncolytic VSV therapy does not correlate with tumor control.

Janelle V, Langlois MP, Lapierre P, Charpentier T, Poliquin L, Lamarre A.

Mol Ther. 2014 Jun;22(6):1198-1210. doi: 10.1038/mt.2014.34. Epub 2014 Mar 4.

17.

Immunovirotherapy with vesicular stomatitis virus and PD-L1 blockade enhances therapeutic outcome in murine acute myeloid leukemia.

Shen W, Patnaik MM, Ruiz A, Russell SJ, Peng KW.

Blood. 2016 Mar 17;127(11):1449-58. doi: 10.1182/blood-2015-06-652503. Epub 2015 Dec 28.

18.

Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-β.

Naik S, Nace R, Barber GN, Russell SJ.

Cancer Gene Ther. 2012 Jul;19(7):443-50. doi: 10.1038/cgt.2012.14. Epub 2012 Apr 20.

19.

Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profiling.

Cockle JV, Rajani K, Zaidi S, Kottke T, Thompson J, Diaz RM, Shim K, Peterson T, Parney IF, Short S, Selby P, Ilett E, Melcher A, Vile R.

Neuro Oncol. 2016 Apr;18(4):518-27. doi: 10.1093/neuonc/nov173. Epub 2015 Sep 26.

20.

Vesicular stomatitis virus oncolytic treatment interferes with tumor-associated dendritic cell functions and abrogates tumor antigen presentation.

Leveille S, Goulet ML, Lichty BD, Hiscott J.

J Virol. 2011 Dec;85(23):12160-9. doi: 10.1128/JVI.05703-11. Epub 2011 Sep 14.

Supplemental Content

Support Center